Literature DB >> 16369012

Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection.

Teresa M Wozniak1, Anthony A Ryan, James A Triccas, Warwick J Britton.   

Abstract

Protection against intracellular pathogens such as Mycobacterium tuberculosis requires the development of Th1-like T-cell responses. This in turn is dependent on the pattern of cytokine produced from dendritic cells (DCs) after infection. Three heterodimeric cytokines, interleukin-12 (IL-12), IL-23, and IL-27, as well as IL-18, contribute to the differentiation and expansion of naive CD4(+) T cells. In this study we compared the effects of plasmids expressing both chains of IL-12, IL-23, or IL-27 as adjuvants for DNA immunization against M. tuberculosis infection. The genes encoding p19 and p40 chains of IL-23 or EBI3 and p28 chains of IL-27 were cloned on either side of a self-cleaving peptide from the FMDV2A protein. The secretion of functional cytokines from transfected cells was detected with bioassays. Supernatant from p2AIL-23-transfected cells induced the release of IL-17 from activated lymphocytes, confirming the presence of bioactive IL-23. Further, supernatant from p2AIL-27-transfected cells stimulated a significant increase in the proliferation of peptide-stimulated transgenic CD4(+) T cells. In initial experiments, M. tuberculosis infection of DCs was more potent at inducing IL-12 and IL-23 secretion than infection with the vaccine strain Mycobacterium bovis bacille Calmette-Guérin (BCG), and no significant upregulation of IL-27 was observed. Coimmunization of C57BL/6 mice with DNA expressing M. tuberculosis antigen 85B (Ag85B; DNA85B) and plasmids expressing IL-23 or IL-12 stimulated stronger Ag85B-specific T-cell proliferative and IFN-gamma responses than DNA85B alone, whereas the addition of p2AIL-27 had no effect. Interestingly, DNA85B codelivered with p2AIL-12, but not p2AIL-23, reduced the immunoglobulin G antibody response. Both p2AIL-23 and p2AIL-12, but not p2AIL-27, enhanced the protective efficacy of DNA85B against aerosol M. tuberculosis challenge. Therefore, both p2AIL-23 and p2AIL-12 are valuable as cytokine adjuvants for increasing the protective antituberculosis immunity induced by DNA vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16369012      PMCID: PMC1346624          DOI: 10.1128/IAI.74.1.557-565.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  69 in total

Review 1.  What kind of message does IL-12/IL-23 bring to macrophages and dendritic cells?

Authors:  Karina R B Bastos; Claudio R F Marinho; Renato Barboza; Momtchilo Russo; José M Alvarez; Maria Regina D'Império Lima
Journal:  Microbes Infect       Date:  2004-05       Impact factor: 2.700

2.  Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model.

Authors:  Anja W Olsen; Ann Williams; Limei M Okkels; Graham Hatch; Peter Andersen
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

3.  The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity.

Authors:  David Artis; Alejandro Villarino; Michael Silverman; Weimian He; Elizabeth M Thornton; Sharon Mu; Shamin Summer; Todd M Covey; Elaine Huang; Hiroki Yoshida; Gary Koretzky; Michael Goldschmidt; Gary D Wu; Fred de Sauvage; Hugh R P Miller; Christiaan J M Saris; Phillip Scott; Christopher A Hunter
Journal:  J Immunol       Date:  2004-11-01       Impact factor: 5.422

4.  Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells.

Authors:  S F Wolf; P A Temple; M Kobayashi; D Young; M Dicig; L Lowe; R Dzialo; L Fitz; C Ferenz; R M Hewick
Journal:  J Immunol       Date:  1991-05-01       Impact factor: 5.422

5.  Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17.

Authors:  Sudeepta Aggarwal; Nico Ghilardi; Ming-Hong Xie; Frederic J de Sauvage; Austin L Gurney
Journal:  J Biol Chem       Date:  2002-11-03       Impact factor: 5.157

6.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

Review 7.  Interleukin-12 and its role in the generation of TH1 cells.

Authors:  G Trinchieri
Journal:  Immunol Today       Date:  1993-07

8.  IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells.

Authors:  Maria Laura Belladonna; Jean-Christophe Renauld; Roberta Bianchi; Carmine Vacca; Francesca Fallarino; Ciriana Orabona; Maria Cristina Fioretti; Ursula Grohmann; Paolo Puccetti
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

9.  Adjuvant activities of novel cytokines, interleukin-23 (IL-23) and IL-27, for induction of hepatitis C virus-specific cytotoxic T lymphocytes in HLA-A*0201 transgenic mice.

Authors:  Masanori Matsui; Osamu Moriya; Maria Laura Belladonna; Sadahiro Kamiya; François A Lemonnier; Takayuki Yoshimoto; Toshitaka Akatsuka
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation provides greater protective immunity against tuberculosis than the existing bacille Calmette-Guérin vaccine.

Authors:  Rachel Pinto; Bernadette M Saunders; Luis R Camacho; Warwick J Britton; Brigitte Gicquel; James A Triccas
Journal:  J Infect Dis       Date:  2003-12-22       Impact factor: 5.226

View more
  24 in total

Review 1.  Th17 cytokines and vaccine-induced immunity.

Authors:  Yinyao Lin; Samantha R Slight; Shabaana A Khader
Journal:  Semin Immunopathol       Date:  2010-01-30       Impact factor: 9.623

Review 2.  IL-17 and Th17 cells in tuberculosis.

Authors:  Egídio Torrado; Andrea M Cooper
Journal:  Cytokine Growth Factor Rev       Date:  2010-11-12       Impact factor: 7.638

Review 3.  Interleukin-12 and tuberculosis: an old story revisited.

Authors:  Andrea M Cooper; Alejandra Solache; Shabaana A Khader
Journal:  Curr Opin Immunol       Date:  2007-08-16       Impact factor: 7.486

4.  Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon.

Authors:  Teresa M Wozniak; Bernadette M Saunders; Anthony A Ryan; Warwick J Britton
Journal:  Infect Immun       Date:  2010-08-02       Impact factor: 3.441

Review 5.  Cytokines and Chemokines in Mycobacterium tuberculosis Infection.

Authors:  Racquel Domingo-Gonzalez; Oliver Prince; Andrea Cooper; Shabaana A Khader
Journal:  Microbiol Spectr       Date:  2016-10

6.  Increased pulmonary tumor necrosis factor alpha, interleukin-6 (IL-6), and IL-17A responses compensate for decreased gamma interferon production in anti-IL-12 autovaccine-treated, Mycobacterium bovis BCG-vaccinated mice.

Authors:  Danielle Freches; Marta Romano; Hannelie Korf; Jean-Christophe Renauld; Jacques Van Snick; Catherine Uyttenhove; Kris Huygen
Journal:  Clin Vaccine Immunol       Date:  2010-11-17

7.  TLR9 regulates the mycobacteria-elicited pulmonary granulomatous immune response in mice through DC-derived Notch ligand delta-like 4.

Authors:  Toshihiro Ito; Matthew Schaller; Cory M Hogaboam; Theodore J Standiford; Matyas Sandor; Nicholas W Lukacs; Stephen W Chensue; Steven L Kunkel
Journal:  J Clin Invest       Date:  2008-12-15       Impact factor: 14.808

8.  Regulatory T cells modulate Th17 responses in patients with positive tuberculin skin test results.

Authors:  Subash Babu; Sajid Q Bhat; N Pavan Kumar; V Kumaraswami; Thomas B Nutman
Journal:  J Infect Dis       Date:  2010-01-01       Impact factor: 5.226

Review 9.  IL-23 and IL-17 in tuberculosis.

Authors:  Shabaana A Khader; Andrea M Cooper
Journal:  Cytokine       Date:  2008-01-22       Impact factor: 3.861

10.  Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis.

Authors:  James A Triccas; Elena Shklovskaya; Joanne Spratt; Anthony A Ryan; Umaimainthan Palendira; Barbara Fazekas de St Groth; Warwick J Britton
Journal:  Infect Immun       Date:  2007-08-27       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.